|
|
Biopartnering Strategies: Maximizing returns from biotechnology deal-makingPublished by: Business Insights Published: Dec. 1, 2006 - 103 Pages Table of ContentsBiopartnering Strategies Executive Summary Biopartnering trends Licensing across the biotechnology lifecycle The biopartnering process Biopartnering for ‘pioneer’ companies Biopartnering for ‘growth’ companies Biopartnering for ‘consolidation’ companies Chapter 1 Biopartnering trends Summary Introduction A maturing biotechnology industry A shift in biopartnering trends Strategic implications Chapter 2 Licensing across the biotechnology lifecycle Summary Introduction The biotech company lifecycle ‘Pioneer’ companies ‘Growth’ companies ‘Consolidation’ companies iv Chapter 3 The biopartnering process Summary Introduction Biopartnering complexity The biopartnering process Biopartnering strategy Opportunity identification Biotechnology out-licensors Biopartnering in-licensors Licensing evaluations Deal-making and agreement Post-deal management and analysis Chapter 4 Biopartnering for ‘pioneer’ companies Summary Introduction Biopartnering objectives Case study: IDM Pharma History Financials Key collaborations Medarex Sanofi-Aventis Other key events Jenner Biotherapies Epimmune Pharmexa Recommendations Chapter 5 Biopartnering for ‘growth' companies Summary Introduction Biopartnering objectives v Case study: Millennium Pharmaceuticals History Financials Key collaborations Sanofi-Aventis Integrilin Ortho Biotech Other key events Leukosite COR Therapeutics Velcade launch Recommendations Chapter 6 Biopartnering for ‘consolidation’ companies Summary 90 Introduction 91 Biopartnering objectives Case study: Biogen IDEC History Financials Key collaborations Schering AG Elan PDL BioPharma Other key events Biogen IDEC merger Conforma Therapeutics Fumapharm Recommendations Chapter 7 Appendix Primary research survey Index vi List of Figures Figure 1.1: Number of biotechnology M&A deals by partner, 1996-2005 Figure 1.2: Biopartnering by in-licensing partner, 1996-2005 Figure 1.3: Biopartnering by stage of development, 1996-2005 Figure 2.4: Evolutionary growth stages for biotech companies Figure 2.5: Biotech company growth drivers Figure 2.6: Key biotech company growth phases Figure 2.7: The biotechnology industry split by development phase Figure 3.8: Expected change in number of biopartnering deals over next 12 months Figure 3.9: Expected change in value of biopartnering deals over next 12 months Figure 3.10: Expected change in number of potential partners chasing each biopartnering deal over next 12 months Figure 3.11: The biopartnering licensing process Figure 3.12: Outside partners involved in identifying potential biopartnering opportunities Figure 3.13: Outside partners involved in due diligence for potential biopartnering opportunities Figure 3.14: Key information shared between partners during negotiations over biopartnering agreements Figure 3.15: Valuation techniques used to support negotiations over biopartnering agreements Figure 3.16: Outside partners involved in the valuation and negotiation of biopartnering agreements Figure 4.17: IDM Pharma’s revenues, 2005 Figure 4.18: IDM Pharma’s key financials, 2000-2005 Figure 5.19: Millennium Pharmaceuticals’ revenues, 2005 83 Figure 5.20: Millennium Pharmaceuticals’ key financials, 1994-2005 Figure 6.21: Biogen IDEC’s revenues, 2005 Figure 6.22: Biogen IDEC’s key financials, 1991-2005 Figure 7.23: Licensing trends survey respondents by company focus Figure 7.24: Licensing trends survey respondents by functional responsibility Figure 7.25: Licensing trends survey respondents by licensing responsibility List of Tables Table 1.1: The global biotechnology industry by region, 2005 Table 1.2: Growth in the global biotechnology industry, 2004-2005 Table 1.3: Biotechnology equity financing trends in North America and Europe, 2004-2005 Table 1.4: Biotechnology blockbusters, 2003-2005 Table 4.5: IDM Pharma’s clinical development pipeline, 2006 Table 5.6: Millennium Pharmaceuticals’ clinical development pipeline, 2006 Table 6.7: Biogen IDEC’s clinical development pipeline, 2006 AbstractOver the past 30 years the biotechnology industry has evolved rapidly, resulting in changes to biopartnering dynamics. Out-licensors now command greater power and leverage over the licensing of their technologies, changing the approach of out-licensing at various stages of the lifecycle and highlighting the need for biotechnology companies to adapt existing strategies to optimize this process. ‘Biopartnering Strategies’ is a unique report from the Drug Discovery series that provides an essential guide to the biopartnering process, for both in-licensing and out-licensing companies. Detailed case studies of biopartnering strategies at different phases of lifecycle development and in-depth analysis of deal trends will ensure that you can identify best practice alliance and licensing strategies and formulate successful deals. Use this report to implement the optimal biopartnering strategy for your company’s needs as it progresses through the ‘pioneer’, ‘growth’ and ‘consolidation’ stages of the lifecycle and ensure you recognize opportunities for growth in this high profit market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||